Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

References

• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• RosenstockJDaileyGMassi-BenedettiMFritscheALinZSalzmanAReduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesDiabetes Care200528495095515793205
   PubMed Web of Science ®Google Scholar
• BarnettADosing of insulin glargine in the treatment of type 2 diabetesClin Ther200729698799917692716
   PubMed Web of Science ®Google Scholar
• ZoungasSChalmersJKengneAPThe efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trialDiabet Res Clin Pract2010892126133
   PubMed Web of Science ®Google Scholar
• BriscoeVJDanisSNHypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology and managementClin Diabetes2006243115121
   Google Scholar
• CryerPEHypoglycemia: the limiting factor in the glycemic management of type I and type II diabetesDiabetologia200245793794812136392
   PubMed Web of Science ®Google Scholar
• UK Hypoglycemia Study GroupRisk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their durationDiabetologia20075061140114717415551
   PubMed Web of Science ®Google Scholar
• DonnellyLAMorrisADFrierBMFrequency and predictors of hypoglycemia in type 2 and insulin-treated type 2 diabetes: a populations-based studyDiabet Med200522674975515910627
   PubMed Web of Science ®Google Scholar
• BarnettAHCradockSFisherMHallGHughesEMiddletonAKey consideration around the risks and consequences of hypoglycemia in people with type 2 diabetesInt J Clin Pract20106481121112920236369
   PubMed Web of Science ®Google Scholar
• BarendseSSinghHFrierBMSpeightJThe impact of hypoglycemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative reviewDiabet Med201229329330221838763
   PubMed Web of Science ®Google Scholar
• NicolucciARossiMCIncretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetesActa Biomed200879318419119260377
   PubMedGoogle Scholar
• BaileyCJKodackMPatient adherence to medication requirements for therapy of type 2 diabetesInt J Clin Pract201165331432221314869
   PubMed Web of Science ®Google Scholar
• Workgroup on hypoglycemia, American Diabetes AssociationDefining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on HypoglycemiaDiabetes Care20052851245124915855602
   PubMed Web of Science ®Google Scholar
• AmielSADixonTMannRJamesonKHypoglycemia in type 2 diabetesDiabet Med200825324525418215172
   PubMed Web of Science ®Google Scholar
• ZammittNNFrierBMHypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalitiesDiabetes Care200528122948296116306561
   PubMed Web of Science ®Google Scholar
• CampbellIWMetformin and the sulphonylureas: the comparative riskHorm Metab Res Suppl1985151051113935560
   PubMedGoogle Scholar
• JermendyGErdeszDNagyLHungarian RECAP GroupOutcomes of adding second hypoglycemia drug after metformin monotherapy failure among type 2 diabetes in HungaryHealth Qual Life Outcomes200868818976457
   PubMed Web of Science ®Google Scholar
• LeiterLAYaleJFChiassonJLHarrisSKleinstiverPSauriolLAssessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia managementCan J Diabet2005293186192
   Google Scholar
• CurrieCJMorganCLPooleCDSharplinPLammertMMcEwanPMultivariate models of health-related utility and the fear of hypoglycemia in people with diabetesCurr Med Res Opin20062281523153416870077
   PubMed Web of Science ®Google Scholar
• WrightADCullCAMacleodKMHolmanRRUKPDS GroupHypoglycemia in type 2 diabeteic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73J Diabetes Complications200620639540117070446
   PubMed Web of Science ®Google Scholar
• ZoungasSPatelAChalmersJADVANCE Collaborative GroupSevere hypoglycemia and risks of vascular events and deathN Engl J Med2010363151410141820925543
   PubMed Web of Science ®Google Scholar
• ZhaoYCampbellCRFonsecaVShiLImpact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetesDiabetes Care20123551126113222432106
   PubMed Web of Science ®Google Scholar
• DesouzaCVBolliGBFonsecaVHypoglycemia, diabetes, and cardiovascular eventsDiabetes Care20103361389139420508232
   PubMed Web of Science ®Google Scholar
• NordinCThe case for hypoglycemia as a proarrhythmic event: basic and clinical evidenceDiabetologia20105381552156120407743
   PubMed Web of Science ®Google Scholar
• Landstedt-HallinLEnglundAAdamsonULinsPEIncreased QT dispersion during hypoglycemia in patients with type 2 diabetes mellitusJ Intern Med1999246329930710475998
   PubMed Web of Science ®Google Scholar
• HalimiSAcute consequences of hypoglycemia in diabetic patientsDiabetes Metab201036 Suppl 3S75S8321211740
   PubMed Web of Science ®Google Scholar
• BauduceauBDoucetJBordierLGarciaCDipuyOMayaudonHHypoglycemia and dementia in diabetic patientsDiabetes Metab201036 Suppl 3S106S11121211731
   PubMed Web of Science ®Google Scholar
• Control GroupTurnbullFMAbrairaCIntensive glucose control and microvascular outcomes in type 2 diabetesDiabetologia200952112288229819655124
   PubMed Web of Science ®Google Scholar
• ChicoAVidal-RiosPSubiràMNovialsAThe continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic controlDiabetes Care20032641153115712663589
   PubMed Web of Science ®Google Scholar
• BakatselosSOHypoglycemia unawarenessDiabetes Res Clin Pract201193 Suppl 1S92S9621864759
   PubMedGoogle Scholar
• HendersonJNAllenKVDearyIJFrierBMHypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awarenessDiabet Med200320121016102114632703
   PubMed Web of Science ®Google Scholar
• MillerCDPhillipsLSZiemerDCGallinaDLCookCBEl-KebbiIMHypoglycemia in patients with type 2 diabetes mellitusArch Intern Med2001161131653165911434798
   PubMedGoogle Scholar
• LeeseGPWangJBroomhallJDARTS/MEMO CollaborationFrequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource useDiabetes Care20032641176118012663593
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes Association; European Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• SaltiIBénardRDetournayBEPIDIAR study groupA population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR study)Diabetes Care200427102306231115451892
   PubMed Web of Science ®Google Scholar
• HolsteinAHammerCHahnMKilamadayilNSKovacsPSevere sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patientsExpert Opin Drug Saf20109567568120553106
   PubMed Web of Science ®Google Scholar
• PunthakeZMillerMELaunerLJACCORD Group of Investigators; ACCORD-MIND InvestigatorsPoor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trialDiabetes Care201235478779322374637
   PubMed Web of Science ®Google Scholar
• SchejterYDTurvallEAckermanZCharacteristic of patients with sulphonylurea-induced hypoglycemiaJ Am Med Dir Assoc201213323423821450199
   PubMed Web of Science ®Google Scholar
• GrecoDAngileriGDrug-induced severe hypoglycemia in type 2 diabetic patients aged 80 years or olderDiabetes Nutr Metab2004171232615163121
   PubMedGoogle Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• JönssonLBolinderBLundkvistJCost of hypoglycemia in patients with type 2 diabetes in SwedenValue Health20069319319816689714
   PubMed Web of Science ®Google Scholar
• FrierBMHow hypoglycemia can affect the life of a person with diabetesDiabetes Metab Res Rev2008242879218088077
   PubMed Web of Science ®Google Scholar
• QuilliamBJSimeoneJCOzbayABKoqutSJThe incidence and costs of hypoglycemia in type 2 diabetesAm J Manag Care2011171067368022106460
   PubMed Web of Science ®Google Scholar
• BrodMChristensenTThomsenTLBushnellDMThe impact of non-severe hypoglycemic events on work productivity and diabetes managementValue Health201114566567121839404
   PubMed Web of Science ®Google Scholar
• CrastoWJarvisJKhuntiKMultifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) studyDiabet Res Clin Pract2011933328336
   PubMed Web of Science ®Google Scholar
• CryerBEGlucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetesEndocrinology201215331039104822166985
   PubMed Web of Science ®Google Scholar
• TaborskyGJJrMundingerTOMinireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemiaEndocrinology201215331055106222315452
   PubMed Web of Science ®Google Scholar
• NataliAFerranniniEEffects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic reviewDiabetologia200649343444116477438
   PubMed Web of Science ®Google Scholar
• RendellMThe role of sulphonylureas in the management of type 2 diabetes mellitusDrugs200464121339135815200348
   PubMed Web of Science ®Google Scholar
• SeinoSTakahashiHTakahashiTShibasakiTTreating diabetes today: matter of selectivity of sulphonylureasDiabetes Obes Metab201214 Suppl 191322118705
   PubMedGoogle Scholar
• StahlMBergerWHigher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureasDiabet Med199916758659010445835
   PubMed Web of Science ®Google Scholar
• PeaceySRRostami-HodjeganAGeorgeETuckerGTHelklerSRThe use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humansJ Clin Endocrinol Metab1997825145814619141533
   PubMed Web of Science ®Google Scholar
• Landstedt-HallinLAdamsonULinsPEOral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab19998493140314510487677
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAADOPT Study GroupGlycemic durability of rosiglitazone, metformin or glyburide monotherapyN Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• ScheenAJClinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trialsDiabet Med1998244311320
   Google Scholar
• MeierJJGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNat Rev Endocrinol201281272874222945360
   PubMed Web of Science ®Google Scholar
• AhrénBDPP-4 inhibitorsBest Pract Res Clin Endocrinol Metab200721451753318054733
   PubMed Web of Science ®Google Scholar
• AhrénBGLP-1 for type 2 diabetesExp Cell Res201131791239124521237153
   PubMed Web of Science ®Google Scholar
• AhrénBLarssonHHolstJJEffects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitusJ Clin Endocrinol Metab19978224734789024239
   PubMed Web of Science ®Google Scholar
• DegnKBBrockBJuhlCBEffect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counter-regulation during hypoglycemiaDiabetes20045392397240315331551
   PubMed Web of Science ®Google Scholar
• AhrénBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab20099441236124319174497
   PubMed Web of Science ®Google Scholar
• DeVriesJHBainSCRodbardHWLiraglutide-Detemir Study GroupSequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targetsDiabetes Care20123571446145422584132
   PubMed Web of Science ®Google Scholar
• RosenstockJAhrénBChowFOnce-weekly GLP-1 receptor agonist albiglutide vs titrated prandial lispro added on to titrated basal glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control weight loss and less hypoglycemiaDiabetes201261 Suppl 1A15
   Google Scholar
• AronsonRRiddleMHomePEfficacy and safety of once-daily lixisenatide in type 2 diabetes insufficiently controlled with basal insulin ± metformin: GetGoal-L studyDiabetologia201255 Suppl 1S8
   Google Scholar
• FonsecaVSchweizerAAlbrechtDBaronMAChangIDejagerSAddition of vildagliptin to insulin improves glycemic control in type 2 diabetesDiabetologia20075061148115517387446
   PubMed Web of Science ®Google Scholar
• VilsbøllTRosenstockJYki-JärvinenHEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes Obes Metab201012216717720092585
   PubMed Web of Science ®Google Scholar
• BarnettAHCharbonnelBDonovanMFlemingDChenREffect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metforminCurr Med Res Opin201228451352322313154
   PubMed Web of Science ®Google Scholar
• BudnitzDSLovegroveMCShehabNRichardsCLEmergency hospitalizations for adverse drug events in older AmericansN Engl J Med2011365212002201222111719
   PubMed Web of Science ®Google Scholar
• PeyrotMBarnettAHMeneghiniLFSchumm-DraegerPMFactors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetes Obese Metab2012
   PubMed Web of Science ®Google Scholar
• LittleSShawJHomePHypoglycemia rates with basal insulin analogsDiabetes Technol Ther201113 Suppl 1S53S6421668338
   PubMed Web of Science ®Google Scholar
• DeFronzoRARattnerREHanJKimDDFinemanMSBaronADEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care20052851092110015855572
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKLEAD-2 Study GroupEfficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 studyDiabetes Care2009321849018931095
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeiningerGSitagliptin Study 020 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care200629122638264317130197
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHissaMNGarberAJSaxagliptin 014 Study GroupThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• BosiECamisascaRPColloberCRochotteEGarberAJEffects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metforminDiabetes Care200730489089517277036
   PubMed Web of Science ®Google Scholar
• NauckMAEllisGCFleckPRWilsonCAMekkiQAlogliptin Study 008 GroupEfficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled studyInt J Clin Pract2009631465519125992
   PubMed Web of Science ®Google Scholar
• TaskinenMRRosenstockJTamminenISafety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab2011131657421114605
   PubMed Web of Science ®Google Scholar